Friday, July 31, 2026

Revolutionary InP Nanosemiconductors: How KAIST Boosted Light Efficiency to 18.1%!

KAIST's breakthrough in semiconductor tech enhances indium phosphide nanocrystals' light efficiency from under 1% to 18.1% through atomic-level control.

High cost keeps breakthrough VHL drug out of reach for Korean patients, oncologist says

Patients with Von Hippel-Lindau syndrome face high treatment costs, limiting access to essential drugs like Welireg, which could reduce surgeries.

Samsung Unveils New Smart Monitors With OLED, AI, and Style

Samsung Electronics launched its 2025 smart monitors, featuring OLED technology and advanced AI capabilities for enhanced viewing.

Tag: obesity treatment

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Wegovy Breaks Records: 3 Million Prescriptions in Just 5 Months – What You Need to Know

Wegovy surpasses 3 million prescriptions in 5 months, marking a significant milestone in the U.S. obesity treatment market.

IVL3021 vs Wegovy: The Future of Long-Acting Obesity Treatments Revealed

Inventage Lab's IVL3021 shows promising long-term obesity treatment results, outperforming competitors with effective weight maintenance strategies.

Celltrion Moves CT-G32 Into Final Preclinical Stage as Global Obesity Trial Preparation Accelerates

Celltrion advances CT-G32, a next-gen obesity treatment, targeting multiple pathways to enhance weight loss while preserving muscle mass.

Metavia Highlights Strong Early Weight-Loss Data for DA-1726 at EASL 2026

MetaVia's obesity treatment candidate 'DA-1726' shows safety and weight loss effects in Phase 1 trials after 54 days.

Inventage Lab Showcases Next-Generation Monthly Obesity Injection Data Ahead of Global Experts at ADA

Inventage Lab presents its next-gen obesity treatment, reducing dosage frequency from weekly to monthly, to U.S. experts.

MetaVia to Present DA-1726 Phase 1 Obesity Trial Data at EASL Congress 2026

Dong-A ST's Meta via will present DA-1726, a dual-action obesity treatment, at the EASL Congress 2026, showcasing promising clinical trial results.

HK inno.N partners with Atomatrix to co-develop AI-based next-generation obesity drug

HK inno.N partners with Atomatrix to develop AI-driven obesity treatments, focusing on novel small-molecule candidates.

Mounjaro prescriptions surge 12-fold in 8 months, surpassing 200,000 monthly for the first time

Mounjaro prescriptions surged over tenfold in eight months, raising concerns about access for patients with obesity amid rising cosmetic demand.

Metabia Begins Dosing First Patient in Phase 1 Part 3 Trial of Obesity Drug DA-1726

Metabia begins Phase 1 trial for DA-1726, a dual-action obesity treatment, aiming for safety and efficacy in weight loss by 2026.

DA-1726: The New Dual-Action Obesity Treatment Set to Transform Weight Loss in 2026

MetaVia's DA-1726 obesity treatment trial approved by U.S. IRB, focusing on dual-action GLP-1 and Glucagon receptors for weight loss.

Unlocking Weight Loss: How Celltrion’s New CT-G32 and Oral Multi-Action Drug Will Change the Game

Celltrion aims to lead the obesity treatment market with innovative drugs, enhancing efficacy and patient convenience through dual approaches.

Why Are Weight-Loss Drugs So Much Pricier in South Korea?

South Korea faces high obesity treatment costs compared to China and Japan, with no insurance coverage, despite potential patent expirations.

Unlocking Weight Loss: Hanmi Pharmaceutical’s Innovative H.O.P Project and the Game-Changing Epaglenatide

Hanmi Pharmaceutical is innovating obesity treatment with efpeglenatide and HM15275, focusing on tailored solutions for Korean patients.

HM15275 Clinical Trials: What You Need to Know About This Groundbreaking Obesity Treatment

Hanmi Pharmaceutical's HM15275 enters Phase 2 trial, aiming to revolutionize obesity treatment and diabetes management by 2030.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.